---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-020446"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2024-05-17T23:59:59+00:00"
generated_at: "2026-06-01T16:14:56.041513+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vivos Therapeutics receives Nasdaq delisting notice for failing minimum equity requirement again

## Summary
- On May 16, 2024, Nasdaq notified Vivos that stockholders' equity fell below $2.5M as of March 31, 2024.
- Company previously regained compliance on May 6, 2024, but new Q1 10-Q filing shows equity < $2.5M.
- Company has filed appeal; delisting is stayed pending Hearing Panel decision.
- If delisted, material adverse effect on stock price, liquidity, capital raising, and reputation.
- No assurance the company can regain or maintain compliance with the minimum equity requirement.

## SEC filing metadata
- accession: 0001493152-24-020446
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2024-05-17T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315224020446/0001493152-24-020446-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315224020446/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-020446
- JSON: https://secwatch.observer/filing/0001493152-24-020446.json
- Plain text: https://secwatch.observer/filing/0001493152-24-020446.txt

## Key facts
- Listing & Compliance Notices
  Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: rch 31, 2024) being less than $2.5 million. The Notice also indicated that Nasdaq would commence delisting proceedings against the Company. The Company has the right to, and has already filed for, an appeal the Nasdaq staff’s determination, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series, to request an additional hearing on this matter before the Hearing Panel. The Company’s appeal has stayed any delisting or suspension action by the Nasdaq staff pending the issuance of the Hearing’s Panel decision. The Company’s common stock will remain listed on Nasdaq, pending th
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716166/000149315224020446/0001493152-24-020446-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.